NR0B2 and metabolic dysfunction-associated steatohepatitis: Likewise, co-treatment with FFAs and INT-767 induced a progressive decrease of FXR expression and a slight increase of SHP, while in the non-NASH environment INT-767 induced a modest reduction of FXR mRNA and a greater increase in SHP expression compared to the FFA-treated samples (6.4 times higher compared to control).